ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

TSHA Taysha Gene Therapies Inc

2.39
0.09 (3.91%)
After Hours
Last Updated: 16:02:01
Delayed by 15 minutes

Period:

Draw Mode:

Volume 890,150
Bid Price 2.30
Ask Price 2.45
News -
Day High 2.45

Low
0.50

52 Week Range

High
3.89

Day Low 2.295
Company Name Stock Ticker Symbol Market Type
Taysha Gene Therapies Inc TSHA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.09 3.91% 2.39 16:02:01
Open Price Low Price High Price Close Price Prev Close
2.35 2.295 2.45 2.395 2.30
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,559 890,150 $ 2.40 $ 2,135,092 - 0.50 - 3.89
Last Trade Time Type Quantity Stock Price Currency
16:00:02 formt 1,094 $ 2.39 USD

Taysha Gene Therapies Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
446.83M 186.96M - 15.45M -111.57M -0.60 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Taysha Gene Therapies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TSHA Message Board. Create One! See More Posts on TSHA Message Board See More Message Board Posts

Historical TSHA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.402.612.1652.381,412,798-0.01-0.42%
1 Month2.833.402.1652.771,905,064-0.44-15.55%
3 Months1.543.551.412.662,963,6400.8555.19%
6 Months2.5353.551.272.242,511,233-0.145-5.72%
1 Year0.653.890.502.282,647,5291.74267.69%
3 Years22.9426.990.502.891,240,971-20.55-89.58%
5 Years22.2533.840.503.311,061,003-19.86-89.26%

Taysha Gene Therapies Description

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

Your Recent History

Delayed Upgrade Clock